Michael Fehlings

6PUBLICATIONS
22CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Innate immunityPredictive and prognostic markersHaematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 14, 2025
PIPLOM: prediction of exogenous peptide loading on major histocompatibility complex class I molecules.

Florian Schmidt, Kanxing Wu, Lorenz Gerber

|Apr 27, 2024
Innate Responses to the Former COVID-19 Vaccine Candidate CVnCoV and Their Relation to Reactogenicity and Adaptive Immunogenicity.

Olaf-Oliver Wolz, Dominik Vahrenhorst, Gianluca Quintini

|Aug 22, 2023
Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapy.

Elaine Lai-Han Leung, Run-Ze Li, Xing-Xing Fan

|Aug 18, 2022
Single-cell analysis reveals clonally expanded tumor-associated CD57+ CD8 T cells are enriched in the periphery of patients with metastatic urothelial cancer responding to PD-L1 blockade.

Michael Fehlings, Leesun Kim, Xiangnan Guan

|Jul 28, 2018
Author Correction: Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

M Fehlings, Y Simoni, H L Penny

|Sep 17, 2017
Checkpoint blockade immunotherapy reshapes the high-dimensional phenotypic heterogeneity of murine intratumoural neoantigen-specific CD8+ T cells.

M Fehlings, Y Simoni, H L Penny

Pageof 1

Frequent Collaborators

3 joint publications

Evan W Newell

2 joint publications

S C Wong

1 joint publications

Alireza Tafazzol

1 joint publications

Oliver A Zill